Lilly Asia Ventures
Xiaodi Su, Ph.D., is a Vice President with Lilly Asia Ventures (LAV). Prior to joining LAV, Xiaodi was a Life Science Specialist at L.E.K., where she led and supported more than 15 projects focusing on pharmaceutical and medtech sectors. Xiaodi holds a Ph.D. in immunology and microbial pathogenesis from the Weill Cornell Graduate School of Medical Sciences and B.S. in biology from Fudan University.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.